HPV Infection Clinical Trial
Official title:
Retrospective Cohort Study to Analyze Whether Prophylactic Vaccination Against HPV Can Reduce the Risk of Recurrence in Women Who Have Received an Excisional Therapy for HSIL / CIN2-3. Recurrence is Defined as the Detection of Infection by the Same HPV Genotype for at Least 6-12 Months (Persistent Infection), and / or Cytological Alteration and / or Cervical and / or Vaginal Histological Lesion of Any Grade (SIL / CIN / VaIN) in Patients With Negative Cotest in the First Post Control.
A retrospective cohort study of women treated by excisional therapy due to HSIL/ CIN at
Clínico San Carlos Hospital between 2012-2018. The effectiveness of prophylactic vaccination
against HPV in women treated for HPV-related disease will be evaluated. For this purpose, the
percentage of cervical lesion recurrence among a group of treated and vaccinated women
against HPV between the years 2015-2018 will be compared with a control group of treated and
non-vaccinated women against HPV since 2012-2015.
It will be an essential requirement that the patient provide a vaccination card from their
health center where there is proof of their immunization status and date of administration.
Inclusion criteria:
- Women older than 18 years who received excisional therapy due to HSIL /CIN injury
confirmed histologically.
- Women who sign informed consent.
- Patients with negative results in the first post-surgery control.
- Patients who have received HPV vaccination and provide vaccination card.
Exclusion criteria:
- Women who do not wish or cannot give their informed consent and / or do not comply with
the requirements of the study.
- Patients treated by an indication other than HSIL/CIN.
- Patients under immunosuppression conditions.
A retrospective cohort study of women treated by excisional therapy due to HSIL/ CIN at
Clínico San Carlos Hospital (Madrid) between 2012-2018. The effectiveness of prophylactic
vaccination against HPV in women treated for HPV-linked disease will be evaluated. For this
purpose, the percentage of lesional recurrence among a group of treated and vaccinated women
against HPV between the years 2015-2018 will be compared with a control group of treated and
non-vaccinated women against HPV since 2012-2015. The data will be obtained through the
review of clinical records.
Our protocol is explained above:
HPV detection method:
The detection of HPV is performed on a liquid basis by means of the CLARK PAPILOMAVIRUS HUMAN
test that detects the presence of the HPV virus (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42,
43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71.72, 73, 81, 82, 83, 84, 85 and
89). The test has a diagnostic sensitivity of 98.2% and a diagnostic specificity of 100% and
analytical specificity: 100%. The analytical sensitivity of this test is 100% when the number
of copies is 1,000 or 10,000 depending on the type of HPV. The Laboratory has carried out
external quality control of the SEAP.
Pre-surgical evaluation:
Those patients with an abnormal cytological result and / or positive HPV tests were referred
to the PTGI consultations of Clínico San Carlos Hospital for evaluation according to the
Cervical Cancer Prevention Guidelines issued by the Spanish Association of Cervical Pathology
and Colposcopy (AEPCC) in 2006 and 2014. These patients underwent colposcopy with biopsy if
necessary +/- determination of HPV. Patients diagnosed with HSIL / CIN 2+ who met the
inclusion criteria were submitted to cervical conization and subsequently enrolled in the
study after signing the informed consent, approved by ethics commission.
We will take into account the date of administration of the first dose of vaccine. The types
of vaccines administered can be: Bivalent vaccine (includes genotypes 16/18), Tetravalent
(includeds genotypes 6, 11, 16 and 18) both funded in the region in different years, or not
funded (Nonavalent vaccine; includes genotypes: 6, 11, 16, 18, 31, 33, 45, 52 and 58). To
define the time of vaccination around the conization date, the administration of the first
dose of vaccine will be taken into account.
Surgical treatment:
Excisional therapy was performed in the operating room on a scheduled basis under local
analgesia and sedation. After infiltration with local anesthetic and vasoconstrictor in the 4
quadrants of the cervix, excisional therapy with diathermic loop is performed under
colposcopy control, obtaining the piece in a single specimen. The piece is oriented with a
long thread at 12:00 h, it is introduced in formaldehyde and send to pathological anatomy for
deferred study. In all cases, immediate endocervical curettage post-treatment was performed.
Clinical follow-up:
The first revision is made 30 days after surgery where patient is informed of histological
results and the date on first control post-treatment based on the diagnosis.
Following the protocol of the AEPCC, in case of non-involvement of margins and negative
endocervical curettage, the patient comes after 6 months from the intervention to perform the
first post-surgery control with co-test. In case of positive endocervical curettage or margin
involvement, the first post-surgery control will be performed at 4 months with cotest +
endocervical study and colposcopy. Persistent disease is defined as the presence of
cytological alteration and / or HPV infection in the first post control performed at 4-6
months after excisional therapy. These patients are excluded from the study, since only those
in which both tests are negative will be included.
Subsequently, a new co-test was performed at 12 months, 24 months and 36 months after the
first post-surgery control. After 3 years of negative testing, the patient is returned to the
current cervical cancer-screening program.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04098744 -
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
|
Phase 2 | |
Completed |
NCT04083196 -
A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
|
Phase 1 | |
Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
Withdrawn |
NCT04430907 -
HPV Vaccine in Postpartum Women
|
||
Recruiting |
NCT02593968 -
Yallaferon in Chinese Population
|
Phase 2 | |
Completed |
NCT04711265 -
Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
|
||
Completed |
NCT02263378 -
A New Supplement for the Immune Response to HPV Infection
|
N/A | |
Completed |
NCT05234112 -
Prevention and Screening Towards Elimination of Cervical Cancer
|
N/A | |
Completed |
NCT04590521 -
HPV Vaccine Immunity in High-risk Women
|
Phase 4 | |
Recruiting |
NCT05829629 -
Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women
|
Phase 1 | |
Recruiting |
NCT06052033 -
Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection
|
N/A | |
Recruiting |
NCT05051852 -
HPV Viral Load in Predicting the Prognosis of LSIL
|
||
Completed |
NCT04155294 -
Re-Evaluation of Annual Cytology Using HPV Testing to Upgrade Prevention in Women Living With HIV
|
||
Active, not recruiting |
NCT06452004 -
Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC)
|
N/A | |
Completed |
NCT06177236 -
Clinic or Self-Sampling for Cervical Cancer Screening
|
N/A | |
Active, not recruiting |
NCT04794660 -
The Study for the "Cervical Cancer Screening and Treatment Algorithms Study Using HPV Testing in Africa"
|
Phase 3 | |
Recruiting |
NCT05509413 -
DEFLAGYN® Vaginal Gel and Spontaneous Remission and Regression of Unclear Cervical Smears and HPV High-risk Infections
|
N/A | |
Recruiting |
NCT06137950 -
Interferon Alpha Therapy for Cervical CINI and HPV Infection
|
Phase 1 | |
Active, not recruiting |
NCT05524025 -
The SPOT-HPV Study
|
||
Recruiting |
NCT04998318 -
1:1 Comparison of the Pocket Colposcope in Kenya
|
N/A |